NEOG
NEOGEN CORP
Key Financials
Operating Income
$-21600000
↑ 98.0%
Revenue
$870.4M
↓ 2.7%
Net Income
$-7900000
↑ 99.3%
Gross Profit
$408.5M
↓ 3.1%
Total Assets
$3.3B
↓ 2.8%
EPS (Diluted)
$-0.04
↑ 99.2%
Total Liabilities
$1.3B
↓ 8.7%
Cash & Equivalents
$185.5M
↑ 43.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 8-K | 8/7/2026 | View on SEC |
| 4 | 8/6/2026 | View on SEC |
| 10-K | 7/30/2026 | View on SEC |
| 8-K | 7/30/2026 | View on SEC |
| SCHEDULE 13G | 7/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NEOG |
| Company Name | NEOGEN CORP |
| CIK | 711377 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 0531 |
| State of Incorporation | MI |
| Phone | 5173729200 |